$92.5 Million is the total value of Asymmetry Capital Management, L.P.'s 34 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 183.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNC | Buy | CENTENE CORP | $6,758,000 | +51.5% | 69,834 | +25.0% | 7.84% | +48.1% |
| INSM | New | INSMED INC | $6,659,000 | – | 213,376 | +100.0% | 7.72% | – |
| JAZZ | Buy | JAZZ PHARMACEUTICALS | $6,156,000 | +26.3% | 42,092 | +34.3% | 7.14% | +23.5% |
| DGX | Buy | QUEST DIAGNOSTICS | $3,579,000 | +4.7% | 38,220 | +24.3% | 4.15% | +2.4% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $3,156,000 | +101.7% | 51,497 | +51.3% | 3.66% | +97.2% |
| NTRA | Buy | NATERA INC | $3,056,000 | +341.0% | 237,118 | +271.6% | 3.54% | +331.1% |
| IONS | New | IONIS PHARMACEUTICALS | $2,837,000 | – | 55,965 | +100.0% | 3.29% | – |
| HMSY | New | HMS HOLDING | $2,818,000 | – | 141,906 | +100.0% | 3.27% | – |
| NVTA | New | INVITAE CORP | $2,753,000 | – | 293,819 | +100.0% | 3.19% | – |
| TCMD | Buy | TACTILE SYSTEMS TECHNOLOGY I | $2,568,000 | +47.5% | 82,976 | +36.2% | 2.98% | +44.2% |
| NITE | New | NIGHTSTAR THERAPEUTICS PLCadr | $2,496,000 | – | 130,007 | +100.0% | 2.90% | – |
| JUNO | New | JUNO THERAPEUTICS INC | $1,380,000 | – | 30,760 | +100.0% | 1.60% | – |
| TVTY | New | TIVITY HEALTH INC | $1,047,000 | – | 25,654 | +100.0% | 1.21% | – |
| HRTX | New | HERON THERAPEUTICS | $1,017,000 | – | 62,962 | +100.0% | 1.18% | – |
| REGN | New | REGENERON PHARMACEUTICALS | $998,000 | – | 2,233 | +100.0% | 1.16% | – |
| SNNAQ | New | SIENNA BIOPHARMACEUTICALS | $926,000 | – | 41,622 | +100.0% | 1.07% | – |
| CBMX | New | COMBIMATRIX CORP | $245,000 | – | 32,641 | +100.0% | 0.28% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.